Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.81 |
| ▸ | NTRK2 | Q16620 | 8/20 | 0.68 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.57 |
| ▸ | RAF1 | P04049 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398755 | 1.00 | NTRK1 (0.81) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL27860281 | 0.92 | NTRK1 (0.82) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL395044 | 0.87 | NTRK2 (0.89) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL395043 | 0.87 | NTRK2 (0.89) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL396214 | 0.81 | NTRK1 (0.85) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL396213 | 0.81 | NTRK1 (0.85) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL14073763 | 0.81 | NTRK2 (0.73) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL396363 | 0.80 | NTRK1 (0.62) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL396364 | 0.80 | NTRK1 (0.62) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL398254 | 0.77 | NTRK2 (1.00) | NTRK1NTRK2NTRK3RAF1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | NTRK1 226/4885NTRK2 235/4885NTRK3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.